HUMAN BABESIOSIS

Citation
A. Gorenflot et al., HUMAN BABESIOSIS, Medecine et maladies infectieuses, 28, 1998, pp. 363-366
Citations number
8
Categorie Soggetti
Infectious Diseases
ISSN journal
0399077X
Volume
28
Year of publication
1998
Pages
363 - 366
Database
ISI
SICI code
0399-077X(1998)28:<363:>2.0.ZU;2-O
Abstract
Hundreds of cases have been reported in the United States, but only 29 cases in Europe. The cattle parasite, B. divergens, was responsible f or most cases in Europe; asplenic individuals were the highest risk gr oup. In severe B. divergens infections, clinical manifestations were c haracterized by a severe intravascular haemolysis and the most efficie nt treatment consisted of a massive blood exchange transfusion and imm ediate subsequent chemotherapy by clindamycin. Mortality rate was high (42% of the splenectomized). In the United States, most cases were ca used by the rodent parasite B. microti. Clinically human B. microti in fection varied widely from an asymptomatic infection to a severe disea se (mortality: 5%). Splenectomized, elderly, immunocompromised and HIV infected patients were predisposed to severe infection. The currently recommanded treatment of symptomatic cases was quinine plus clindamyc in, A few other cases of human babesial infection have been described in China, Egypt, Mexico, South Africa and Taiwan.